Telix Pharmaceuticals is trading at A$17.62, up +4.45%, after investors continued repricing the company following the September 14 FDA approval of Pixclara, the first FDA-approved FET-PET imaging drug for glioma.
- The approval opens U.S. commercial access and a potential new revenue stream
- The broader biotech sector was weaker
- The company-specific regulatory milestone remains the clearest explanation for the positive move